Prognostication of vulvar cancer based on p14ARF status: Molecular assessment of transcript and protein

Annals of Surgical Oncology

Volumn 20, Issue 1, 2013, Pages 31-39

  Lavorato Rocha, André Mourão ^a   De Melo Maia, Beatriz ^a   Rodrigues, Iara Sant'Ana ^a   Stiepcich, Mônica Maria Ágata ^b   Baiocchi, Glauco ^a   Cestari, Flávia Munhoz Da Silva ^a   Carvalho, Kátia Cândido ^c   Soares, Fernando Augusto ^a   Rocha, Rafael Malagoli ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b Fleury   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER TISSUE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PATHOPHYSIOLOGY; PERINEURIUM; PREDICTIVE VALUE; PREVALENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; TUMOR VOLUME; VULVA CARCINOMA; VULVAR SQUAMOUS CELL CARCINOMA; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD VESSELS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; PERIPHERAL NERVES; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; VULVAR NEOPLASMS; YOUNG ADULT;

EID: 84871784181     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2560-7     Document Type: Article

References (44)

1. Crum CP. Carcinoma of the vulva: epidemiology and pathogenesis. Obstet Gynecol. 1992;79:448-54.
2. FIGO Committee on Gynecologic Oncology and IGCS Guidelines Committee. Staging Classifications and Clinical Practice Guidelines of Gynecologic Cancers. USA: FIGO, 2nd edn, 2003.
3. Fons G, Burger MP, Ten Kate FJ, van der Velden J. Identification of potential prognostic markers for vulvar cancer using immunohistochemical staining of tissue microarrays. Int J Gynecol Pathol. 2007;26:188e93.
4. Sadalla JC, Lourenço SV, Sotto MN, Baracat EC, Carvalho JP. Claudin and p53 expression in vulvar lichen sclerosus and squamous-cell carcinoma. J Clin Pathol. 2011;64(10):853-7.
5. McConnell DT, Miller ID, Parkin DE, Murray GI. p53 protein expression in a population-based series of primary vulval squamous cell carcinoma and immediate adjacent field change. Gynecol Oncol. 1997;67(3):248-54.
6. Kagie MJ, Kenter GG, Tollenaar RA, Hermans J, Trimbos JB, Fleuren GJ. p53 protein overexpression is common and independent of human papillomavirus infection in squamous cell carcinoma of the vulva. Cancer. 1997;80:1228-33.
7. Knopp S, Nesland JM, Tropé C, Holm R. p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma. Am J Clin Pathol. 2006;126:266-76.
8. ARF, interacts with Mdm2 and neutralizes Mdm2's inhibition of p53. Cell. 1998;92:713-23.
9. ARF, participates in a regulatory feedback loop with p53 and Mdm2. EMBO J. 1998;17:5001-14.
10. ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A. 1999;96:6937-41.
11. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes Hdm2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppressor pathways. Cell. 1998;92:725-34.
12. Sanchez-Aguilera A, Sanchez-Beato M, Garcia JF, Prieto I, Pollan M, Piris MA. P14 nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood. 2002;99:1411-8.
13. ARF links the tumor suppressors pRB and p53. Nature. 1998;395:124-5.
14. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-50.
15. Fox H, Wells M. Recent advances in the pathology of the vulva. Histopathology. 2003;42:209-16.
16. Soufir N, Queille S, Liboutet M, et al. Inactivation of the CDKN2A and the p53 tumour suppressor genes in external genital carcinomas and their precursors. Br J Dermatol. 2007;156(3):448-53.
17. Watanabe T, Katayama Y, Yoshino A, et al. Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol. 2007;17:5-10.
18. He J, Qiao JB, Zhu H. p14ARF promoter region methylation as a marker for gliomas diagnosis. Med Oncol. 2011;28(4):1218-24.
19. Kohlberger P, Kainz C, Breitenecker G, et al. Prognostic value of immunohistochemically detected p53 expression in vulvar carcinoma. Cancer. 1995;76:1786-89.
20. Kagie MJ, Kenter GG, Zomerdijk-Nooijen Y, et al. Human papillomavirus infection in squamous cell carcinoma of the vulva, in various synchronous epithelial changes and in normal vulvar skin. Gynecol Oncol. 1997;67:178-83.
21. Scheistrøen M, Tropé C, Pettersen EO, Nesland JM. p53 protein expression in squamous cell carcinoma of the vulva. Cancer. 1999;85:1133-8.
22. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Löning T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer. 1995;63:639-45.
23. Ogi K, Toyota M, Ohe-Toyota M, et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res. 2002;8:3164-71.
24. Sailasree R, Abhilash A, Sathyan KM, Nalinakumari KR, Thomas S, Kannan S. Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17(2):414-20.
25. Brandenberger AW, Rüdlinger R, Hänggi W, Bersinger NA, Dreher E. Detection of human papillomavirus in vulvar carcinoma: a study by in situ hybridisation. Arch Gynecol Obstet. 1992;252:31-35.
26. Lee YY, Wilczynski SP, Chumakov A, Chih D, Koeffler HP. Carcinoma of the vulva: HPV and p53 mutations. Oncogene. 1994;9:1655-9.
27. Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus in squamous cell carcinoma of the vulva by polymerase chain reaction. Obstet Gynecol. 1997;89:81-4.
28. Lerma E, Matias-Guiu X, Lee SJ, Prat J. Squamous cell carcinoma of the vulva: study of ploidy, HPV, p53, and pRb. Int J Gynecol Pathol. 1999;18:191-7.
29. Biedermann K, Dandachi N, Trattner M, et al. Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirus in archival cervical cancer tissue. J Clin Microbiol. 2004;42:3758-65.
30. Monk BJ, Burger RA, Lin F, Parham G, Vasilev SA, Wilczynski SP. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol 1995;85:709-15.
31. Toki T, Kurman RJ, Park JS, Kessis T, Daniel RW, Shah KV. Probable nonpapillomavirus etiology of squamous cell carcinoma of the vulva in older women: a clinicopathologic study using in situ hybridization and polymerase chain reaction. Int J Gynecol Pathol. 1991;10:107-25.
32. Hørding U, Junge J, Daugaard S, Lundvall F, Poulsen H, Bock JE. Vulvar squamous cell carcinoma and papillomaviruses: indications for two different etiologies. Gynecol Oncol. 1994;52:241-6.
33. Trimble CL, Hildesheim A, Brinton LA, Shah KV, Kurman RJ. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol. 1996;87:59-64.
34. Nogueira MC, Guedes Neto Ede P, Rosa MW, et al. Immunohistochemical expression of p16 and p53 in vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva. Pathol Oncol Res. 2006;12(3):153-7.
35. Röijer E, Dahlenfors R, Mark J, Stenman G. Observations by chromosome banding, FISH and immunohistochemistry in an adenoid cystic carcinoma with del(17)(p13) as the sole deviation. Virchows Arch. 1997;430:339-42.
36. Vanin K, Scurry J, Thorne H, Yuen K, Ramsay RG. Overexpression of wild-type p53 in lichen sclerosus adjacent to human papillomavirus-negative vulvar cancer. J Invest Dermatol. 2002;119:1027-33.
37. Osakabe M, Hayashi M, Katayama Y, et al. Characteristics of vulvar squamous cell carcinoma in Japanese women. Pathol Int. 2007; 57:322-7.
38. Pinto AP, Miron A, Yassin Y, et al. Differentiated vulvar intraepithelial neoplasia contains TP53 mutations and is genetically linked to vulvar squamous cell carcinoma. Mod Pathol. 2010;23:404-12.
39. Hacker NF. Vulvar cancer. In: Berek JS, Hacker NF, editors. Berek & Hacker's gynecologic oncology. 5th edn. Philadelphia: Williams & Wilkins; 2010:576-92.
40. de Hullu JA, van der Zee AG. Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol. 2006;60(1):38-58.
41. Homesley HD, Bundy BN, Sedlis A, et al. Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study). Gynecol Oncol. 1993;49:279-83.
42. De Hullu JA, Hollema H, Lolkema S, et al. Vulvar carcinoma. The price of less radical surgery. Cancer. 2002;95:2331-8.
43. Woelber L, Kock L, Gieseking F, et al. Clinical management of primary vulvar cancer. Eur J Cancer. 2011;47(15):2315-21.
44. Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008;26(6):884-9.